, Volume 64, Issue 1, pp 43–47 | Cite as

Effects of exenatide and liraglutide on postchallenge glucose disposal in individuals with normal glucose tolerance

  • Yushi HirotaEmail author
  • Tomokazu Matsuda
  • Shinsuke Nakajima
  • Michinori Takabe
  • Naoko Hashimoto
  • Tomoaki Nakamura
  • Yuko Okada
  • Kazuhiko Sakaguchi
  • Wataru Ogawa
Original Article



Glucagon-like peptide–1 receptor agonists (GLP-1RAs) are categorized as short- or long-acting types, but information regarding differences in the effects of these two types on postprandial glucose disposal has been limited. We have now investigated the effects of exenatide and liraglutide (short- and long-acting GLP-1RAs, respectively) on glucose disposal during an oral glucose tolerance test (OGTT).


Fourteen healthy volunteers with normal glucose tolerance underwent three OGTTs, which were performed without pharmacological intervention or after a single administration of exenatide or liraglutide at 30 min and 10 h, respectively, before test initiation. The three OGTTs were performed with intervals of at least 7 days between successive tests and within a period of 2 months.


Exenatide, but not liraglutide, markedly decelerated the peak of both plasma glucose and serum insulin levels during the OGTT, with the peaks of both glucose and insulin concentrations occurring at 150 min after test initiation with exenatide compared with 30 min in the control condition or with liraglutide. Exenatide and liraglutide reduced the area under the curve for plasma glucose levels during the OGTT by similar extents, whereas that for serum insulin levels was reduced only by exenatide.


Our results suggest that exenatide decelerates the increase in plasma glucose levels through inhibition of glucose absorption and that it exerts an insulin-sparing action after glucose challenge.


Exenatide Liraglutide Oral glucose tolerance test Japanese 



We thank Yuki Nishimoto, Kei Yoshino, Takehito Takeuchi, Hiroshi Miura, and Yasushi Nakagawa for assistance with data collection.

Compliance with ethical standards

Conflict of interest

T.M., K.S., and W.O. have received lecture fees from Novo Nordisk; Y.H., K.S., and W.O. have received lecture fees from Eli Lilly; and Y.H. and W.O. have received lecture fees from Astra Zeneca. W.O. has received research support from Novo Nordisk, Eli Lilly, and Astra Zeneca.

Ethical approval

This exploratory, open-label, single-center study was approved by the ethics committee of Kobe University Graduate School of Medicine (approval no. 230021), conforms to the provisions of the Declaration of Helsinki, and is registered in the University Hospital Medical Information Network (UMIN000006858).

Informed consent

All the individuals provided written informed consent to participation in the study.


  1. 1.
    J.J. Meier, GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8, 728–742 (2012)CrossRefGoogle Scholar
  2. 2.
    T. Vilsbøll, M. Christensen, A.E. Junker, F.K. Knop, L.L. Gluud, Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 344, d7771 (2012)CrossRefGoogle Scholar
  3. 3.
    Z.Z. Htike, F. Zaccardi, D. Papamargaritis, D.R. Webb, K. Khunti, M.J. Davies, Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes. Metab. 19, 524–536 (2017)CrossRefGoogle Scholar
  4. 4.
    Z. Li, Y. Zhang, X. Quan, Z. Yang, X. Zeng, L. Ji, F. Sun, S. Zhan, Efficacy and acceptability of glycemic control of glucagon-like peptide-1 receptor agonists among type 2 diabetes: a systematic review and network meta-analysis. PLoS ONE 11, e0154206 (2016)CrossRefGoogle Scholar
  5. 5.
    S.P. Marso, G.H. Daniels, K. Brown-Frandsen, P. Kristensen, J.F. Mann, M.A. Nauck, S.E. Nissen, S. Pocock, N.R. Poulter, L.S. Ravn, W.M. Steinberg, M. Stockner, B. Zinman, R.M. Bergenstal, J.B. Buse; LEADER Steering Committee; LEADER Trial Investigators, Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016)CrossRefGoogle Scholar
  6. 6.
    S.P. Marso, S.C. Bain, A. Consoli, F.G. Eliaschewitz, E. Jódar, L.A. Leiter, I. Lingvay, J. Rosenstock, J. Seufert, M.L. Warren, V. Woo, O. Hansen, A.G. Holst, J. Pettersson, T. Vilsbøll; SUSTAIN-6 Investigators, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016)CrossRefGoogle Scholar
  7. 7.
    M. Gutniak, C. Orskov, J.J. Holst, B. Ahrén, S. Efendic, Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 326, 1316–1322 (1992)CrossRefGoogle Scholar
  8. 8.
    M.A. Nauck, N. Kleine, C. Orskov, J.J. Holst, B. Willms, W. Creutzfeldt, Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36, 741–744 (1993)CrossRefGoogle Scholar
  9. 9.
    J.J. Meier, G. Kemmeries, J.J. Holst, M.A. Nauck, Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 54, 2212–2218 (2005)CrossRefGoogle Scholar
  10. 10.
    J.J. Meier, B. Gallwitz, S. Salmen, O. Goetze, J.J. Holst, W.E. Schmidt, M.A. Nauck, Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 88, 2719–2725 (2003)CrossRefGoogle Scholar
  11. 11.
    M. Zander, S. Madsbad, J.L. Madsen, J.J. Holst, Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359, 824–830 (2002)CrossRefGoogle Scholar
  12. 12.
    A. Flint, A. Raben, A. Astrup, J.J. Holst, Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101, 515–520 (1998)CrossRefGoogle Scholar
  13. 13.
    M.D. Turton, D. O’Shea, I. Gunn, S.A. Beak, C.M. Edwards, K. Meeran, S.J. Choi, G.M. Taylor, M.M. Heath, P.D. Lambert, J.P. Wilding, D.M. Smith, M.A. Ghatei, J. Herbert, S.R. Bloom, A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69–72 (1996)CrossRefGoogle Scholar
  14. 14.
    A. Astrup, S. Rössner, L. Van Gaal, A. Rissanen, L. Niskanen, M. Al Hakim, J. Madsen, M.F. Rasmussen, M.E. Lean; NN8022-1807 Study Group, Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374, 1606–1616 (2009)CrossRefGoogle Scholar
  15. 15.
    C.W. le Roux, A. Astrup, K. Fujioka, F. Greenway, D.C.W. Lau, L. Van Gaal, R.V. Ortiz, J.P.H. Wilding, T.V. Skjøth, L.S. Manning, X. Pi-Sunyer; SCALE Obesity Prediabetes NN8022-1839 Study Group, 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 389, 1399–1409 (2017)CrossRefGoogle Scholar
  16. 16.
    A. Lund, F.K. Knop, T. Vilsbøll, Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur. J. Intern. Med. 25, 407–414 (2014)CrossRefGoogle Scholar
  17. 17.
    J.B. Buse, J. Rosenstock, G. Sesti, W.E. Schmidt, E. Montanya, J.H. Brett, M. Zychma, L. Blonde; LEAD-6 Study Group, Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374, 39–47 (2009)CrossRefGoogle Scholar
  18. 18.
    C. Kapitza, T. Forst, H.V. Coester, F. Poitiers, P. Ruus, A. Hincelin-Méry, Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes. Metab. 15, 642–649 (2013)CrossRefGoogle Scholar
  19. 19.
    M.A. Nauck, G. Kemmeries, J.J. Holst, J.J. Meier, Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 60, 1561–1565 (2011)CrossRefGoogle Scholar
  20. 20.
    P.A. Kothare, H. Linnebjerg, Y. Isaka, K. Uenaka, A. Yamamura, K.P. Yeo, A. de la Peña, C.H. Teng, K. Mace, M. Fineman, H. Shigeta, Y. Sakata, S. Irie, Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J. Clin. Pharmacol. 48, 1389–1399 (2008)CrossRefGoogle Scholar
  21. 21.
    S. Kageyama, K. Hirao, A. Shimizu, Y. Matsumura, M. Zdravkovic, M.F. Rasmussen, S. Irie, Tolerability, pharmacokinetics, and pharmacodynamics of liraglutide, long-acting human GLP-1 analogue―phase I studies in Japanese healthy subjects and subjects with type 2 diabetes. Endocrinol. Diabetol. 24, 95–104 (2007). [in Japanese]Google Scholar
  22. 22.
    S.S. Thazhath, C.S. Marathe, T. Wu, J. Chang, J. Khoo, P. Kuo, H.L. Checklin, M.J. Bound, R.S. Rigda, B. Crouch, K.L. Jones, M. Horowitz, C.K. Rayner, The glucagon-like peptide 1 receptor agonist exenatide inhibits small intestinal motility, flow, transit, and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomized controlled trial. Diabetes 65, 269–275 (2016)Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Diabetes and Endocrinology, Department of Internal MedicineKobe University Graduate School of MedicineKobeJapan
  2. 2.Division of General Internal Medicine, Department of Internal MedicineKobe University Graduate School of MedicineKobeJapan

Personalised recommendations